Depression Pipeline Highlights - H2 2016 Update Report - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Depression Pipeline Highlights - 2016 Update" drug pipelines to their offering.

Depression Pipeline Highlights - 2016 Update, provides most up-to-date information on key pipeline products in the global Depression market. It covers emerging therapies for Depression in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Depression pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Depression pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Depression pipeline products by the company.

Short-term Launch Highlights:

Find out which Depression pipeline products will be launched in the US and Ex-US till 2019.

Key Topics Covered:

1. Depression Pipeline by Stages

2. Depression Pipeline by Drug Class

3. Depression Pipeline by Company

4. Depression Phase 3 Clinical Trial Insights

5. Depression Phase 2 Clinical Trial Insights

6. Depression Phase 1 Clinical Trial Insights

7. Depression Preclinical Research Insights

8. Depression Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/lpd3qk/depression.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Mental Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Mental Disorders Drugs